アポト―ス・バイオサイエンシズ（APTO）Aptose Biosciences Inc. - 米国株銘柄紹介 | 米国株を知る場所 nasdaqchart（ナスダックチャート）

APTOのチャート

APTOの企業情報

symbol	APTO
会社名	Aptose Biosciences Inc （アポト―ス・バイオサイエンシズ）
分野（sector）	Health Care ヘルスケア
産業（industry）	Biotechnology: Biological Products (No Diagnostic Substances)
業種	バイオテクノロジ―_メディカルリサ―チ医療関連（Health Care）
概要	事業概要アプトス・バイオサイエンセス（Aptose Biosciences Inc）（旧名：Lorus Therapeutics Inc.）は、生命科学会社。同社は、安全性プロファイルのある効果的抗癌治療法の発見・研究・開発を行う。また、前臨床から完成第I相臨床試験に至るまで様々な段階の製品で、多様的抗がん製品パイプラインを確立する。アポト―ス・バイオサイエンシズはカナダのバイオ医薬品企業。主に腫瘍への対応標的治療薬の発見と開発に従事する。同社はさまざまな臨床段階の医薬品と市場性のある抗がん医薬品を手掛け、主要パイプライン「LOR-253」は、急性骨髄性白血病と骨髄異形成症候群を含む高度な血液悪性腫瘍向けのものである。本社はオンタリオ州。
本社所在地	251 Consumers Road Suite 1105 Toronto Ontario M2J 4R3 CAN
代表者氏名	William Glenn Rice ウィリアム・グレン・ライス
代表者役職名	Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）
電話番号	+1 647-479-9828
設立年月日	31656
市場名	NASDAQ Small Cap
ipoyear	―年
従業員数	20人
url	www.aptose.com
nasdaq_url	https://www.nasdaq.com/symbol/apto
adr_tso	―
EBITDA	EBITDA（百万ドル） -23.14960
終値（lastsale）	2.1
時価総額（marketcap）	72781121.7
時価総額	時価総額（百万ドル） 68.17641
売上高	売上高（百万ドル） 0.00000
企業価値(EV)	企業価値(EV)（百万ドル） 49.71241
当期純利益	当期純利益（百万ドル） -23.04202
決算概要	決算概要 BRIEF: For the six months ended 30 June 2018 Aptose Biosciences Inc revenues was not reported. Net loss increased from $5.7M to $17.1M. Higher net loss reflects Research and development - Balancing val increase from $0K to $5M (expense) Program cost increase from $1.9M to $4.5M (expense) Stock-based compensation increase from $386K to $2.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.30 to -$0.54.

APTOのテクニカル分析

APTOのニュース

Aptose Biosciences Stock Trades Higher After Q4 Earnings: Technical Levels To Watch 2021/03/24 21:10:04 Benzinga

Aptose Biosciences Inc. (NASDAQ: APTO ) shares traded higher after the company’s release of fourth-quarter results Tuesday. The stock gained 66.21% in Wednesday's regular session, closing at $6.10. Aptose shares were giving back 7.05% at last check during after-hours trading. Aptose Bioscience Short-Term Chart Analysis: The 5-minute chart shown above displays the chart is trading in a channel between the prices of $5.60 and $6.80. The price was unable to break above and consolidate over the $5.60 level during premarket trading on Wednesday. The price after the market open was able to cross above this level and hold as a … Full story available on Benzinga.com

The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study 2021/03/05 13:15:09 Benzinga

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Therapeutics, Inc. (NASDAQ: DYN ) (reacted to fourth-quarter results) Epizyme, Inc. (NASDAQ: EPZM ) Freeline Therapeutics Holdings plc (NASDAQ: FRLN ) Galecto, Inc. (NASDAQ: GLTO ) Inhibikase Therapeutics, Inc.

The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida 2021/02/26 13:16:52 Benzinga

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.

ACT NOW: 1 Pharma Stock That Could Triple in Value 2021/02/01 13:00:27 The Motley Fool Canada

Aptose Biosciences Inc. (TSX:APS) is a science-driven biotechnology company producing medicines to cure cancer. The company's shares could rise significantly from current levels. The post ACT NOW: 1 Pharma Stock That Could Triple in Value appeared first on The Motley Fool Canada .

Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020 2020/10/27 20:01:00 GlobeNewswire

SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly…